OOIR: Observatory of International Research

Papers

(The TQCC of Clinical & Translational Immunology is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Endothelial cells are not productively infected by SARS‐CoV‐2	94
Antibodies against type I interferon: detection and association with severe clinical outcome in COVID‐19 patients	82
A scalable serology solution for profiling humoral immune responses to SARS‐CoV‐2 infection and vaccination	81
CAR‐NK cells: the next wave of cellular therapy for cancer	74
Allogeneic CD20‐targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B‐cell lymphoma models	59
Comprehensive analysis of SARS‐CoV‐2 antibody dynamics in New Zealand	52
Patient‐derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR‐T cells in vitro	48
Preclinical development of a molecular clamp‐stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2	46
Pattern of circulating SARS‐CoV‐2‐specific antibody‐secreting and memory B‐cell generation in patients with acute COVID‐19	46
Dynamics of antibodies to SARS‐CoV‐2 in convalescent plasma donors	45
Rheumatoid arthritis CD14⁺ monocytes display metabolic and inflammatory dysfunction, a phenotype that precedes clinical manifestation of disease	43
Pathogenesis of autoimmune demyelination: from multiple sclerosis to neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody‐associated disease	41
Arrested development: suppression of NK cell function in the tumor microenvironment	39
Kinetics of peripheral blood neutrophils in severe coronavirus disease 2019	39
The up‐to‐date pathophysiology of Kawasaki disease	38
Decline in neutralising antibody responses, but sustained T‐cell immunity, in COVID‐19 patients at 7 months post‐infection	37
Natural killer cells in inflammatory autoimmune diseases	37
The complex interplay between endoplasmic reticulum stress and the NLRP3 inflammasome: a potential therapeutic target for inflammatory disorders	35
RGD‐binding integrins and TGF‐β in SARS‐CoV‐2 infections – novel targets to treat COVID‐19 patients?	34
Type 1 conventional dendritic cells and interferons are required for spontaneous CD4⁺ and CD8⁺ T‐cell protective responses to breast cancer	34
SARS‐CoV‐2‐specific humoral and cellular immunity persists through 9 months irrespective of COVID‐19 severity at hospitalisation	34
Cardiovascular disease in SARS‐CoV‐2 infection	31
Cerebrospinal fluid metabolomics: detection of neuroinflammation in human central nervous system disease	31
Prophylactic antigen‐specific T‐cells targeting seven viral and fungal pathogens after allogeneic haemopoietic stem cell transplant	31
Molecular and cellular mechanisms of itch and pain in atopic dermatitis and implications for novel therapeutics	29

TGF‐β‐secreting regulatory B cells: unsung players in immune regulation	29
Ligelizumab treatment for severe asthma: learnings from the clinical development programme	28
Systematic evaluation of SARS‐CoV‐2 antigens enables a highly specific and sensitive multiplex serological COVID‐19 assay	28
Off‐target effects of bacillus Calmette–Guérin vaccination on immune responses to SARS‐CoV‐2: implications for protection against severe COVID‐19	27
Lysine methyltransferase G9a is an important modulator of trained immunity	26
An acetate‐yielding diet imprints an immune and anti‐microbial programme against enteric infection	26
Robust correlations across six SARS‐CoV‐2 serology assays detecting distinct antibody features	26
Influenza, but not SARS‐CoV‐2, infection induces a rapid interferon response that wanes with age and diminished tissue‐resident memory CD8⁺ T cells	26
High levels of soluble CD25 in COVID‐19 severity suggest a divergence between anti‐viral and pro‐inflammatory T‐cell responses	26
Circular RNA TRAPPC6B inhibits intracellular Mycobacterium tuberculosis growth while inducing autophagy in macrophages by targeting microRNA‐874‐3p	25
Blunted sFasL signalling exacerbates TNF‐driven neutrophil necroptosis in critically ill COVID‐19 patients	25
Autoantibodies against complement component C1q in systemic lupus erythematosus	23
Humoral immunity against SARS‐CoV‐2 variants including omicron in solid organ transplant recipients after three doses of a COVID‐19 mRNA vaccine	23
Novel high‐affinity EGFRvIII‐specific chimeric antigen receptor T cells effectively eliminate human glioblastoma	23
Inflammatory marker trajectories associated with frailty and ageing in a 20‐year longitudinal study	22
Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis	22
Memory stem T cells modified with a redesigned CD30‐chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma	22
Impact of SARS‐CoV‐2 infection on vaccine‐induced immune responses over time	21
Modelling the tumor immune microenvironment for precision immunotherapy	19
Optimising the IgG‐degrading enzyme treatment regimen for enhanced adeno‐associated virus transduction in the presence of neutralising antibodies	19
Differential transcriptional and functional properties of regulatory T cells in HIV‐infected individuals on antiretroviral therapy and long‐term non‐progressors	19
Heterogeneous magnitude of immunological memory to SARS‐CoV‐2 in recovered individuals	19
Landscape of T‐cell repertoires with public COVID‐19‐associated T‐cell receptors in pre‐pandemic risk cohorts	18
Characteristics of T‐cell responses in COVID‐19 patients with prolonged SARS‐CoV‐2 positivity – a cohort study	18
Next‐generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cells	18
Nalfurafine reduces neuroinflammation and drives remyelination in models of CNS demyelinating disease	18
SLAMF8 expression predicts the efficacy of anti‐PD1 immunotherapy in gastrointestinal cancers	18
Circulating CD8⁺ mucosal‐associated invariant T cells correlate with improved treatment responses and overall survival in anti‐PD‐1‐treated melanoma patients	18
Increased GM‐CSF‐producing NCR^‐ ILC3s and neutrophils in the intestinal mucosa exacerbate inflammatory bowel disease	17
Quantification and role of innate lymphoid cell subsets in Chronic Obstructive Pulmonary Disease	17
Exploiting the CRISPR‐Cas9 gene‐editing system for human cancers and immunotherapy	17
Whole‐blood cytokine secretion assay as a high‐throughput alternative for assessing the cell‐mediated immunity profile after two doses of an adjuvanted SARS‐CoV‐2 recombinant protein vaccine candidate	17
Sustained low‐dose interleukin‐2 therapy alleviates pathogenic humoral immunity via elevating the Tfr/Tfh ratio in lupus	17
C‐reactive protein flare‐response predicts long‐term efficacy to first‐line anti‐PD‐1‐based combination therapy in metastatic renal cell carcinoma	17
Inflammasome activation: from molecular mechanisms to autoinflammation	16
Epigenetic programming underpins B‐cell dysfunction in peanut and multi‐food allergy	16
TIGIT blockade enhances NK cell activity against autologous HIV‐1‐infected CD4⁺ T cells	16
Inflammation neuroscience: neuro‐immune crosstalk and interfaces	16
Human neutralising antibodies elicited by SARS‐CoV‐2 non‐D614G variants offer cross‐protection against the SARS‐CoV‐2 D614G variant	16
SARS‐CoV‐2 triggers complement activation through interactions with heparan sulfate	16
IgM and IgA augmented autoantibody signatures improve early‐stage detection of colorectal cancer prior to nodal and distant spread	16
IL‐17 drives salivary gland dysfunction via inhibiting TRPC1‐mediated calcium movement in Sjögren’s syndrome	15
Tear antibodies to SARS‐CoV‐2: implications for transmission	15
Mutated GM‐CSF‐based CAR‐T cells targeting CD116/CD131 complexes exhibit enhanced anti‐tumor effects against acute myeloid leukaemia	15
Human regulatory T cells locally differentiate and are functionally heterogeneous within the inflamed arthritic joint	15
Tumor‐associated neutrophils (TANs) in human carcinoma‐draining lymph nodes: a novel TAN compartment	15
Antibodies to neutralising epitopes synergistically block the interaction of the receptor‐binding domain of SARS‐CoV‐2 to ACE 2	15
Proinsulin‐specific T‐cell responses correlate with estimated c‐peptide and predict partial remission duration in type 1 diabetes	15
Adenoviral vector‐based platforms for developing effective vaccines to combat respiratory viral infections	15
T‐cell response after first dose of BNT162b2 SARS‐CoV‐2 vaccine among healthcare workers with previous infection or cross‐reactive immunity	15

Intratumoral injection of caerin 1.1 and 1.9 peptides increases the efficacy of vaccinated TC‐1 tumor‐bearing mice with PD‐1 blockade by modulating macrophage heterogeneity and the activation of CD8	14
Perivascular macrophages create an intravascular niche for CD8⁺ T cell localisation prior to the onset of fatal experimental cerebral malaria	14
Deficient DNASE1L3 facilitates neutrophil extracellular traps‐induced invasion via cyclic GMP‐AMP synthase and the non‐canonical NF‐κB pathway in diabetic hepatocellular carcinoma	14
Regulation of the human NK cell compartment by pathogens and vaccines	14
Adaptive immunity to human coronaviruses is widespread but low in magnitude	14
High expression of CD38 and MHC class II on CD8⁺ T cells during severe influenza disease reflects bystander activation and trogocytosis	13
Validation and performance of a multiplex serology assay to quantify antibody responses following SARS‐CoV‐2 infection or vaccination	13
SARS‐CoV‐2 sculpts the immune system to induce sustained virus‐specific naïve‐like and memory B‐cell responses	13
Understanding the tumor microenvironment in head and neck squamous cell carcinoma	13
Parallel detection of SARS‐CoV‐2 epitopes reveals dynamic immunodominance profiles of CD8⁺ T memory cells in convalescent COVID‐19 donors	13
Impact of adaptive natural killer cells, KLRC2 genotype and cytomegalovirus reactivation on late mortality in patients with severe COVID‐19 lung disease	13
Glycolipid‐peptide conjugate vaccines elicit CD8⁺ T‐cell responses and prevent breast cancer metastasis	12
YTHDF2 promotes temozolomide resistance in glioblastoma by activation of the Akt and NF‐κB signalling pathways via inhibiting EPHB3 and TNFAIP3	12
High‐resolution analysis of individual spike peptide‐specific CD4⁺ T‐cell responses in vaccine recipients and COVID‐19 patients	12
Adoptive T‐cell therapy targeting Epstein–Barr virus as a treatment for multiple sclerosis	12